Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 8 studies | 28% ± 15% | |
| mesothelial cell | 7 studies | 40% ± 15% | |
| epithelial cell | 5 studies | 38% ± 25% | |
| microglial cell | 4 studies | 39% ± 19% | |
| smooth muscle cell | 4 studies | 30% ± 6% | |
| macrophage | 3 studies | 31% ± 14% | |
| myofibroblast cell | 3 studies | 39% ± 16% | |
| astrocyte | 3 studies | 39% ± 21% | |
| retinal pigment epithelial cell | 3 studies | 44% ± 11% | |
| connective tissue cell | 3 studies | 24% ± 4% | |
| chondrocyte | 3 studies | 40% ± 17% |
Insufficient scRNA-seq data for expression of ROR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 3069.19 | 244 / 245 | 86% | 12.09 | 433 / 502 |
| ovary | 100% | 2785.59 | 180 / 180 | 78% | 12.15 | 336 / 430 |
| adrenal gland | 98% | 1159.78 | 253 / 258 | 79% | 20.17 | 181 / 230 |
| uterus | 100% | 4712.05 | 170 / 170 | 69% | 13.40 | 316 / 459 |
| lung | 98% | 1151.23 | 569 / 578 | 70% | 7.80 | 806 / 1155 |
| thymus | 100% | 1195.35 | 650 / 653 | 64% | 9.99 | 386 / 605 |
| stomach | 98% | 2387.08 | 351 / 359 | 64% | 7.93 | 184 / 286 |
| esophagus | 94% | 2659.77 | 1362 / 1445 | 68% | 10.52 | 124 / 183 |
| breast | 69% | 992.24 | 315 / 459 | 91% | 15.32 | 1021 / 1118 |
| bladder | 100% | 3667.95 | 21 / 21 | 55% | 6.05 | 277 / 504 |
| intestine | 94% | 4201.63 | 907 / 966 | 54% | 5.19 | 285 / 527 |
| skin | 94% | 985.43 | 1699 / 1809 | 25% | 2.46 | 119 / 472 |
| pancreas | 13% | 62.09 | 42 / 328 | 88% | 12.27 | 157 / 178 |
| spleen | 87% | 661.84 | 210 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 80% | 12.94 | 36 / 45 |
| adipose | 67% | 828.42 | 802 / 1204 | 0% | 0 | 0 / 0 |
| kidney | 24% | 140.99 | 21 / 89 | 30% | 3.28 | 266 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 52% | 4.15 | 15 / 29 |
| heart | 50% | 878.81 | 434 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 21% | 170.23 | 284 / 1335 | 0% | 0 | 0 / 0 |
| liver | 2% | 7.94 | 4 / 226 | 9% | 0.86 | 36 / 406 |
| brain | 3% | 18.46 | 82 / 2642 | 7% | 0.93 | 52 / 705 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.21 | 4 / 80 |
| muscle | 0% | 0.59 | 1 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0045651 | Biological process | positive regulation of macrophage differentiation |
| GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
| GO_0010976 | Biological process | positive regulation of neuron projection development |
| GO_0007165 | Biological process | signal transduction |
| GO_0007275 | Biological process | multicellular organism development |
| GO_0033674 | Biological process | positive regulation of kinase activity |
| GO_0030539 | Biological process | male genitalia development |
| GO_0030335 | Biological process | positive regulation of cell migration |
| GO_0150045 | Biological process | regulation of synaptic signaling by nitric oxide |
| GO_0030282 | Biological process | bone mineralization |
| GO_1905517 | Biological process | macrophage migration |
| GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0014002 | Biological process | astrocyte development |
| GO_0051968 | Biological process | positive regulation of synaptic transmission, glutamatergic |
| GO_0016055 | Biological process | Wnt signaling pathway |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0099175 | Biological process | regulation of postsynapse organization |
| GO_0098978 | Cellular component | glutamatergic synapse |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005874 | Cellular component | microtubule |
| GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
| GO_0043025 | Cellular component | neuronal cell body |
| GO_0098794 | Cellular component | postsynapse |
| GO_0030425 | Cellular component | dendrite |
| GO_0009986 | Cellular component | cell surface |
| GO_0017147 | Molecular function | Wnt-protein binding |
| GO_0015026 | Molecular function | coreceptor activity |
| GO_0031435 | Molecular function | mitogen-activated protein kinase kinase kinase binding |
| GO_0004714 | Molecular function | transmembrane receptor protein tyrosine kinase activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0005524 | Molecular function | ATP binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ROR2 |
| Protein name | Tyrosine-protein kinase transmembrane receptor ROR2 (EC 2.7.10.1) (Neurotrophic tyrosine kinase, receptor-related 2) Receptor tyrosine kinase-like orphan receptor 2 Receptor tyrosine kinase like orphan receptor 2 (Receptor tyrosine kinase-like orphan receptor 2, isoform CRA_b) |
| Synonyms | NTRKR2 hCG_1985325 |
| Description | FUNCTION: Tyrosine-protein kinase receptor which may be involved in the early formation of the chondrocytes. It seems to be required for cartilage and growth plate development (By similarity). Phosphorylates YWHAB, leading to induction of osteogenesis and bone formation . In contrast, has also been shown to have very little tyrosine kinase activity in vitro. May act as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling . . |
| Accessions | B1APY4 Q01974 A1L4F5 ENST00000375708.4 ENST00000375715.5 |
